EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Octapharma’s balanced portfolio built on a very special juice

Kate Khair

The Journal of Haemophilia Practice · 2013

DOI: 10.17225/jhp.00023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Haemophilia Practice, 2013. Verfasst von Kate Khair. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair

Zitieren

APA

Khair, K. (2013). Octapharma’s balanced portfolio built on a very special juice. The Journal of Haemophilia Practice. https://doi.org/10.17225/jhp.00023

Vancouver

Khair K. Octapharma’s balanced portfolio built on a very special juice. The Journal of Haemophilia Practice. 2013. doi:10.17225/jhp.00023

BibTeX
@article{Khair2013,
  author = {Khair, Kate},
  title = {Octapharma’s balanced portfolio built on a very special juice},
  journal = {The Journal of Haemophilia Practice},
  year = {2013},
  doi = {10.17225/jhp.00023}
}
Kostenlos starten →